pSivida Corp (PSDV) Reports Australia/New Zealand Distribution Agreement For ILUVIEN® For DME
4/28/2014 10:48:29 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN® for the treatment of diabetic macular edema (DME). Under the agreement, STA also will handle all regulatory and commercial activities for ILUVIEN in those countries.
Help employers find you! Check out all the jobs and post your resume.
comments powered by